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, Summary: Reference methods for lipids, lipoproteins, and apolipoproteins have been developed for use äs
part of an accuracy base .for institutional, national, or international reference Systems. A widely accepted
reference method exists only for total cholesterol. Well described Interim or institutional in-house reference
methods have been established for the other lipids, lipoproteins, and apolipoproteins. The major criteria for
a reference method are
1) scientific basis,
2) sound principles,
3) available calibration and control materials,
4) traceability to a definitive method or a point of reference, and
5) applicability to reference materials that provide traceability to clinical methods and transferability to other
reference laboratories.
The total cholesterol reference method of the U. S. National Reference System demonstrates how a reference
method can be developed and applied. Reference methods now available can lead to an accepted international
accuracy base for the clinically useful lipid, lipoprotein, and apolipoprotein measurements.
n ro uc on
 a reference method and reference material play a
Reference methods are esseiitial coinponents of the significant role in tränsferring the accuracy base of a
accuracy base of any established reference System for definitive method to the clinical laboratory. Reference
lipids, lipoproteins, and apolipoproteins. A stable ac- methods afe considered acceptable when they possess
curacy base depends upon availability, of a stable
 x ^ . . . .
reference method and reference materials. Together, *> known ™mmum bias versus a definitive method,
2) known sound scientific basis,
*) Contribution of the International Föderation of Clinical _ N ._ t , t ._ , ,. - ^Chemistry (IFCC) Working Group on Apolipoprotein Ref- 3) available calibration and quality control reference
erence Methods established at the Centers for Disease Cori- material, and
trol and the IFCC Committee on Apolipoproteins (S. M. . .
Marcovina, chairman, /. /. Albers, J. C. Fruchart, M. Ros- 4) traceability to clinical methods and their secondary
seneu, J. Shepherd) of the IFCC Scientific Division (H. Grel· serum reference material.
fing, chairman, M. M. Müller, vice chairman).
Based on a lecture given at the Symposium "Reference Meth- The more widely available reference methods designed
ods in Clinical Chemistry - Objectives Trends, Problems"
 f widespread use and application must be validated
of the Congress Biochemische Analytik 90, München, May ^ *;*;8y 1990 by the less available definitive method (1). A punfied
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primary Standard is required to calibrate the definitive
method and reference method while commutable sec-
ondary serum reference materials are used to calibrate
clinical methods of lipids, lipoproteins, and apolipo-
proteins. A higher productivity or throughput than
the definitive method provides is desirable to satisfy
multiple demands placed upon a reference method.
Reference methods are developed to assure accuracy
of clinically useful laboratory procedures. Procedures
for lipid, lipoprotein, and apolipoprotein considered
highly useful to the clinicians in the detection, pre-
vention, and control of coronary heart disease and
secondary hyperlipidaemia diseases are quantitative
measurements of total cholesterol, triacylglycerol,
high-density lipoprotein (HDL)2) and low-density li-
poprotein (LDL), cholesterol, and apolipoproteins -
and B. These therefore will be discussed here.
Reference methods have been established at the Cen-
ters for Disease Control (CDC) for total cholesterol,
triacylglycerol, HDL cholesterol, and apolipoprotein
A-1 and B (2). The total cholesterol method has been
accepted äs the total cholesterol reference method of
the US National Reference System for Cholesterol
established by the National Committee for Clinical
Laboratory Standards (NCCLS) (3). The US Na.
tional Reference System for Cholesterol comprises the
isotope dilution and mass spectrometric definitive
method of the National Institute of Standards and
Technology (NIST) (4), CDC modified Abell-Levy-
Brodie—Kendall (5) total cholesterol reference method
(6, 7), NIST-certified pure cholesterol Standard, and
NIST- and CDC-certified serum based secondary ref-
erence material (8). The NCCLS has accepted the
CDC in-house reference methods for triacylglycerol
and HDL cholesterol äs NCCLS Interim reference
methodological principles for the U. S. National Ref-
erence System. CDC and the Committee on Apoli-
poproteins of the International Federation of Clinical
Chemistry (IFCC) are collaborating in studies de-
signed to select candidate reference methods for apo-
lipoproteins A-l and B.
The total cholesterol reference method will be dis-
cussed in greater detail than those of the other lipids,
in order to illustrate the characteristics, requisites,
and applications of a reference method and its role
in standardization.
2) Non-standard abbreviations:
CDC Centers for Disease Control
„ NIST National Institute for Standards and Technology
SRM Standard Reference Material
RIA radioimmunoassay
VLDL very low-density lipoprotein
IDL intermediate-density lipoprotein
LDL low-density lipoprotein
HDL high-density lipoprotein
Essential Characteristics of a Reference Method
The major criteria for a reference method are
1) scientific basis,
2) sound principles,
• r
3) available calibration and control materials,
4) traceability to a definitive method or a point of
reference,
5) applicability to reference materials that provide
traceability to clinical methods, and
6) transferability to
(9-12).
other reference laboratories
The scientific basis is judged by accuracy, precison,
linearity of dose-response, specificity, stability of re-
agents, interferences, recovery, and ruggedness. Sound
principles demand that each analytical step must be
defined and controlled, possess appropriate sensitiv-
ity, permit accurate sampling and dilutions, use stable
equipment, cälculate results by accepted procedures,
and be subject to acceptable analysis of variaüce. Each
reference method should use a defined purified pri-
mary Standard or defined serum biolögicäl reference
preparation for use in calibration or monitoring. The
serum reference materials should have minimum ma-
trix effects, be stable over time, and permit valid
assignment of mass values. Directions for the refer-
ence method should be written so clearly that the
reference method caii be transferred to other labora-
tories without any instructions other than the direc-
tions. These essential characteristics form the criteria
that a method must meet to be considered äs a can-
didate reference method for the measurement of lip-
ids, lipoproteins, and apolipoproteins in serum or
other body fluids.
Total Cholesterol Reference Method
In 1975, the Cholesterol Reference Method Study
Group of the American Associätion for Clinical
Chemistry (AACC) invited the CDC to .develop-a
candidate total cholesterol reference method. During
the five-year develöpment pefiod (1977-1982), five
Potential candidate methods were selected, optimized,
and compared. The top two methods (Abell—Levy—
Brodie-^-Kendall (5) and an enzymic procedure) were
selected on the basis of these studies, and were then
compared with the NIST-developed Isotope dilution-
mass spectrometric definitive method (4). On the basis
of these comparisons, the American Associätion for
Clinical Chemistry Cholesterol Reference Method
Study Group selected the Abell^ Levy—Brodle—Ken-
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dall method äs the recommended total cholesterol
reference method (5). The Abell—Levy — Brodie —
Kendall method was next subjected to extensive vali-
dation studies (6) and a transferability study with 14
collaborating lipid laboratories throughout the
United States (7). The transferability study demon-
strated that the recommended reference method per-
mits laboratories to attain a coefficient of Variation
(CV) of less than 1.5% within the laboratory and CV
of less than 3.0% among the 14 laboratories. The
mean percent bias value of the 14 laboratories com-
pared with that of the CDC was less than l % for six
of the 14 laboratories, less than 1.5% for 12, and less
than 3% for all 14 laboratories (7). Interestingly, a
preliminary readiness testing and competence evalu-
ation predicted the quality of analytical performance
exhibited during the transferability testing.
The total cholesterol reference method procedure in-
| cludes the following steps: a 0.5-ml sample in 20 g/l
| alcoholic KOH undergoes hydrolysis at 50 °C for l h;
! the hydrolysate is extracted with hexane by vigorous
; shaking at 25 °C for 15 min; an aliquot of hexane is
1
 evaporated in a vacuum oven at 55 °C; colour is
developed by reaction with a reagent formed from 20
parts acetic anhydride, l part H2SO4, and 10 parts
glacial acetic acid at 25 °C for exactly 30 min; and an
absorbance reading is taken at 620 nm in a flow-
through cuvette.
Calibration is performed with NIST pure cholesterol
Standard reference material 911b (6). Since 1978, an-
alytical performance of the total cholesterol reference
method at CDC has exhibited a CV of less than l %
and a bias rarely above 1% on frozen serum pools
(tab. 1).
Tab. 1. Performance of total
CDC 1989
cholesterol reference method,
October November Cumulative
Expected value = 179.8 mg/dl (4.65 mmol/1)
N 32 22
Meau 180.2 (4.66) 180.5 (4.67)
Bias (%) + . 8 +0.37
CV(%) 0.58 0.59
Expected value = 276.2 mg/dl (7.14 mmol/1)
N 31 18
Mean 277.0 (7.16) 247.7 (7.10)
Bias (%) 4-0.30 -0.53
CV (%) 0.64 1.10
Expected value = 298.6 mg/dl (7.72 mmöi/1)
N 12 8
Mean 300.8 (7.78) 301.6 (7.80)
Bias(%) +0.71 +1.09
CV (%) 0.38 0.43
190
180.0 (4.65)
+0.09
1.53
183
275.2 (7.12)
-0.38
1.07
239
298.9 (7.73)
+0.97
0.97
CDC and NIST have collaborated since 1978 to main-
tain a defined accuracy base with the CDC reference
method and the NIST definitive method. Five frozen
serum pools were used originally to compare the ref-
erence method with the definitive method. The agree-
ment between the two methods was considered excel-
lent with a difference of less than 1.0% of all five
pools (2). In 1989, comparisons of the reference
method and definitive method revealed excellent
agreement (0.41 %) on Standard Solutions (SRM 91 Ib)
and good agreement (1.6%) on fresh, frozen, or ly-
ophilized sera (l 3). Unpublished experimental studies
at CDC on potential interferences in the reference
method indicate that this difference in level of results
between the reference method and definitive method
results largely from sterols in serum (14).
Since 1961, the CDC total cholesterol reference
method has served äs a part of the accuracy base for
the CDC-National Heart, Lung, and Blood Institute
Lipid Standardization Programme. This accuracy
base has been transferred through frozen serum ref-
erence materials distributed to the several hundred
U.S. participants, äs well äs to many international
laboratories. The reliability of the reference method
has made it possible to assure the accuracy of labo-
ratories supporting more than 30 cardiovascular epi-
demiologic or clinical investigations coordinated by
CDC-National Heart, Lung, and Blood Institute,
such äs the Coronary Drug Project (15), the Lipid
Research Clinics (16), Multiple Risk Factor Interven-
tion Trial (17), and the Hypertension Detection and
Follow-up Study (18).
The NCCLS's National Reference System for the
Clinical Laboratory Council has adopted the CDC
reference method äs its national reference method for
cholesterol (19). The National Reference System for
the Clinical Laboratory Council has designated the
NIST definitive method, the CDC reference method,
the NIST certified pure cholesterol SRM 911, and the
CDC^certified serum-based secondary reference ma-
terials äs the components of the National Reference
System for Cholesterol (3).
The National Reference Method Laboratory Network
has been formed by CDC to provide resources for
acourate calibration of manufacturers' total choles-
terol analytical diagnostic products and accurate con-
firmatory analysis for clinical laboratories (2). Cali-
bration with fresh specimens has been necessary for
some of the new total cholesterol reagent analytical
Systems that exhibit matrix effects with liquid, frozen,
or lyophilized reference materials. The protocol used
by the Network utilizes the NCCLS recommendation
on procedure for comparison of methods using fresh
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 29,1991 / No. 4
272 Symposium: Reference Methods in Clinical Chemistry
patient specimens (20). Currently, the network in-
cludes nine laboratories in the United States and one
in the Netherlands: University of Minnesota, Baylor
College of Medicine, Wisconsin State Laboratory of
Hygiene, Cleveland Clinic Foundation, New York
State Department of Health, Northwest Lipid Re-
search Center in Seattle, Pennsylvania State Depart-
ment of Health, Washington University in St. Louis,
USDA Nutrition Research Center on Aging at Tufts
University, and Rotterdam Academic Hospital. Net-
work laboratories must document a CV of less than
2% and a bias of less than 1.5% at 3-month intervals
in the CDC-National Heart, Lung, and Blood Insti-
tute Lipid Standardization Program.
Interim Triacylglycerol Reference Method
An in-house triacylglycerol reference method was es-
tablished at CDC in 1963 on the basis of the method
of Carlson (21, 22) and the techniques of Van Handel
& Zilversmii (23) and Lofland (24). The in-house
method involves silicic acid-chloroform extraction for
l h at 25 °C, evaporation of an aliquot in a vacuum
oven at 50 °C, chemical hydrolysis with 2.5 g/l alco-
holic KOH for 30 min at 70 °C, allowing the solution
to stand overnight at 4 °C after neutralization with
0.1 mol/1 H2SO4, colour development by metaperiod-
ate-arsenite-chromotropic acid reagent at 95 °C, and
reading of the cooled solution in flow cell at 570 nm.
The specificity of this method is largely due to the
chloroform-silicic acid extraction procedure that re-
moves free glycerol and retains minimally monoacyl-
glycerol and diacylglycerol. The primary Standard can
be either pure triolein, pure palmitin, or a 2: l mix-
ture, respectively. Glycerol or mannitol can be used
äs a primary Standard in calibrating or monitoring
the last step in the method that analyzes the free
glycerol. Laboratories' findings can lack comparabil-
ity if different primary Standards are used, unless
results are expressed in mmol/1. True bias is not
Tab. 2. Triacylglycerol reference method performance, CDC
1989
N
Expected value
Mean
Bias (%)
CV (%)
Expected value
Mean
Bias (%)
CV (%)
October
20
= 0.907 mmol/1
0.918
+ 1.20
4.0
= 2.381 mmol/1
2.39
-l· 0.49
3.9
November
12
0.910
+ 0.33
2.2
2.35
-1.41
2.7
Cumulative
364
0.917
+ 1.13
5.6
2.36
-0.86
3.0
known, because a definitive method is not available.
The attainable precision usually ranges between 3%
and5%CV(tab.2).
The major problems with the use of this triacylglycerol
method äs a reference method at CDC are
1) extraction with carcinogenic CHC13,
2) difficulty arising from the presence of silicic acid
"fines" or very small pärticles in extracts,
3) impurity, instability and a potentially different de-
gree of hydrolysis of different triacylglycerols,
4) unknown commutability of lyophilized reference
material, and
5) questionable transferability of this chromotropic
acid method.
Investigators are searching for a triacylglycerol ref-
erence method that may cireumvent these problems'.
This CDC in-house triacylglycerol reference method
has been designated äs the Interim triacylglycerol can-
didate reference method for the National Reference
System and serves äs the selected reference method
for the CDC-maintained accuracy base for the CDC-
National Heart, Lung, and Blood Institute Lipid
Standardization Programme and for the dedicated
laboratories of National Heart, Lung, and Blood In-
stitute clinical and epidemiologic cardiovascular iii-
vestigations and trials.
Interim HDL Cholesterol Reference Method
A CDC in-house HDL cholesterol reference method
combines removal of very low density lipoprotein
cholesterol (VLDL) by the Beta Quan ultracentrifugal
procedure (25), isolation of HDL cholesterol by pre-
cipitation of LDL cholesterol from the l .006 kg/l Beta
Quan bottom fraction by 46 mmol/1 manganese and
1.3 g/l heparin reagent (25), and cholesterol analysis
of the HDL cholesterol supernate by the National
Reference System for Cholesterol total cholesterol
reference method (6,7). The primary Standard is NIST
cholesterol SRM 911 (8), and it must cover the low
ränge öf serum HDL cholesterol values, which is
different from the ränge of serum total cholesterol.
HDL cholesterol measurements are monitored with
both pure cholesterol and frözen, fresh serum second-
ary Standards. Precision for the CDC in-house HDL
cholesterol reference method on low cholesterol prl·
mary Standards is between 1% and 2% CV, and on
frözen serum secondary reference niaterials, it is be-
tween 2.5% and 4% (tab. 3). True bias is not known
because a definitive inethod is not available for HDL
cholesterol measuremeiits. , *
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Tab. 3. HOL cholesterol reference method performance, CDC
1989
Pool
prepared
7-84
2-87
HDL cholesterol mean
N mg/dl
470 47.0
149 39.0
concentration
mmol/1
1.22
1.01
Total
CV %
3.0
3.3
Low cholesterol mean concentration
3-85
8-87
488 51.1
72 52.5
1.32
1.36
1.8
1.6
This HDL cholesterol method has served äs the ref-
erence method for the CDC-National Heart, Lung,
and Blood Institute epidemiological and clinical in-
vestigations (25).
The HDL cholesterol method is also used äs part of
l the CDC interim reference methods for VLDL and
j LDL cholesterol. The CDC interim reference method
! values for VLDL cholesterol are calculated from
I serum total cholesterol minus Beta Quan bottom frac-
tion cholesterol determined by the National Reference
System for Cholesterol cholesterol reference method.
The CDC interim LDL reference method values are
calculated from Beta Quan bottom fraction choles-
terol minus HDL cholesterol determined by National
Reference System for Cholesterol total cholesterol
method. This interim LDL reference method deter-
mines not only the LDL, but also intermediate-density
lipoproteins (IDL) and Lp(a) constituents äs rneas-
ured in Friedewald procedure (26) or in the l .006 —
1.063 kg/l ultracentrifugal fractions (25).
The major problems with the interim HDL cholesterol
reference method are that it has
1) nö definitive method,
2) no accepted primary Standard, and
3) questionable traceability to clinical and research
laboratory methods that possess matrix effects.
CDC In-House Apolipoprotein B Radioimmunoassay
Method
A competitive radioimmunoassay (RIA) method has
been selected and is being evaluated äs an interim
apolipoprotein B reference method for use in the
International Apolipoprotein Standardization Pro-
gramme conducted by CDC. To conduct this immu-
noassay, a l: 100 dilution of sample is incubated with
goat anti-LDL antibody at 37 °C for l h in the pres-
ence of cholate and bovine serum albumin; iodinated
LDL is added, and the solution is further incubated
at 4 °C for 16h; donkey anti-anti-LDL second anti-
body is added, and the solution is incubated at 4 °C
for 3 h in the presence of polyethyleneglycol; centrif-
ugation is conducted at 2500 min""1 for 20 min; the
supernant is decanted with blotting; and radioactivity
of precipitate is counted. The primary Standard is an
LDL solution ultracentrifugally prepared at 1.030 —
l .050 kg/l (27). The results are calculated from bound/
free ratio counts per minute versus log concentration
within the ränge of 0.25 — 2.00 g/l of apolipoprotein
B. This method has an intrassay variability of about
2% CV and an interassay of less than 6% CV. True
bias is not known since a definitive method is not
available for apolipoprotein B measurements.
Major problems exist inherently in any potential im-
munological reference method for apolipoprotein B
measurements. Immunoassays require sensitivity and
specificity of antisera, highly accurate dilutions, linear
and parallel dose-response curves, and reproducible
preparations of primary Standards. Reported among-
laboratory Variation within the methods can have an
average CV of between 20% and 25% for apolipo-
protein B (28). The proposed (at 1.030-1.050 kg/l
ultracentrifugally prepared) LDL primary Standard
provides an LDL preparation with decreased IDL
and Lp(a) but shows limited immunological stability
and uncertainty in protein analysis (29). Tracing an
apolipoprotein B reference method to clinical and
research apolipoprotein B immunochemical methods
is difficult because of large matrix effects of reference
materials in certain methods (28, 30).
During 1990, the IFCC Committee on Apolipopro-
teins and manufacturers of apolipoprotein diagnostic
products are evalüating potential stabilized liquid
serum reference materials for use äs apolipoprotein B
secondary serum Standards. These materials, along
with frozen serum pools stored at — 70 °C, will be
used in Standardization programmes of manufactur-
ers' apolipoprotein B diagnostic products. Difficulties
and current recommendations on the Standardization
of apolipoprotein B measurements have been thor-
oughly discussed in recent publications (31 —33).
CDC In-House Apolipoprotein A-l Reference Method
A competitive RIA method, developed for use äs a
CDC in-house reference method for apolipoprotein
A-l, is similar to the method developed for apolipo-
protein B. The apolipoprotein A-l RIA method uti-
lizes goat polyclonal anti-apolipoprotein A-l anti-
serum, and solid phase lactoperoxidase for the iodi-
nation of purified apolipoprotein A-l. The apolipo-
protein A-l primary Standard is a freshly prepared,
liquid, delipidated, purified preparation, confirmed
for purity by amino acid analysis. The Standard dis-
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 29,1991 / No» 4
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placement curve ranges between 0.50 and 2.0 g/l where
serum samples are diluted l : 100 in one Step. Precision
measurements give an intra-assay CV of about 2%,
and an inter-assay CV of less than 6%. Tracing clin-
ical methods to a reference method for apolipoprotein
A-l should not be difficult since among-method
source of Variation is negligible for apolipoprotein Α-
Ι measurements (28).
A lyophilized, purified, and delipidated proposed apo-
lipoprotein A-l primary Standard is currently being
evaluated by the European Cummunity Bureau of
Reference in Br ssels and the IFCC Committee on
Apolipoproteins. Manufacturers of apolipoprotein di-
agnostic products and this IFCC committee are col-
laborating to develop a commutable lyophilized apo-
lipoprotein A-l serum secondary Standard. This proj-
ect seeks to gain comparability of results among com-
mercial apolipoprotein A-l diagnostic products. The
CDC is supporting this effort by analysing these ref-
erence materials with the RIA method and studying
Potential primary Standards and their problems.
Conclusions - r
A reference method has been developed for total
cholesterol for national and international reference
Systems. Interim reference methods are being used for
triacylglycerol, HDL cholesterol and LDL cholesterol
measurements. Potential candidate reference methods
are being developed and evaluated for apolipoprotein
Α-Λ and B measurements by different apolipoprotein
investig tors. Continuing worldwide efforts to im-
prove the methodology should lead to an accepted
international accuracy base for the clinically useful
lipid, lipoprotein, and apolipoprotein measurements.
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